To compare the progression-free survival (PFS) of CC-92480 (also known as BMS-986348), bortezomib and dexamethasone (480Vd) to that of pomalidomide, bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma (RRMM)

In Stage 1, to determine the dose of CC-92480 in combination with bortezomib and dexamethasone to continue in Stage 2 of the study - In Stage 1, to determine the plasma concentrations of CC-92480 in combination with bortezomib and dexamethasone - To compare overall survival (OS) between 480Vd and PVd in subjects with RRMM • To evaluate additional efficacy parameters in subjects with RRMM treated with 480Vd compared to PVd - To evaluate minimal residual disease (MRD) negativity rate in subjects treated with 480Vd compared to those treated with PVd - To evaluate safety of 480Vd compared to PVd in subjects with RRMM - In subjects randomized to Stage 2, to evaluate cancer-related symptoms and healthrelated quality of life (HRQoL) using the European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) and the European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) in subjects treated with 480Vd compared to PVd

Relapsed or refractory multiple myeloma (RRMM) who have received 1 to 3 prior lines of antimyeloma therapy.

Auswahl: 1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF). 2. Subject has documented diagnosis of MM and measurable disease, defined as any of the following: a. M-protein ≥ 0.5 g/dL by serum protein electrophoresis (sPEP) or b. M-protein ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) or, c. For subjects without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio. 3. Subject has received 1 to 3 prior lines of antimyeloma therapy. (Note: One line can contain several phases [eg, induction, (with or without) hematopoietic stem cell transplant, (with or without) consolidation, and/or (with or without) maintenance therapy) See APPENDIX J. 4. Subject must have received prior treatment with a lenalidomide-containing regimen. 5. Subject must have documented disease progression during or after their last antimyeloma regimen.

Auswahl: 1. Subject who has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor. 2. For subjects with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or subject discontinued bortezomib due to toxicity. 3. Subject has previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of initiating study treatment.